Epizyme: Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass.-(BUSINESS WIRE)-Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel... Read MoreThe post Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update appeared first on citybiz.
Read full article »
Epizyme is a Massachusetts-based biopharmaceutical company that develops and commercializes novel epigenetic medicines for the treatment of cancer.
Read more